Search research articles
Contact Us
Filters
Showing results (51-60 of 116) with videos related to
Page
of 12
Sort By:
Cancer Research
|
April 1, 1974
Histological analysis of the antimetastatic effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane
A J Salsbury, K Burrage, K Hellmann
British Medical Journal
|
November 7, 1970
Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic
A J Salsbury, K Burrage, K Hellmann
European Journal of Cancer & Clinical Oncology
|
June 1, 1989
The pyrimido-pyrimidine derivatives RA233 and RX-RA85 affect cell cycle distribution of two murine tumour cell lines
R B Lichtner, G Hutchinson, K Hellmann
Cancer Chemotherapy and Pharmacology
|
January 1, 1982
Razoxane penetration into the cerebrospinal fluid of rats
N Greig, F Xiao-Chang, K Hellmann
Cancer Chemotherapy Reports
|
December 1, 1971
Blood clearance of ICRF 159 (NSC-129943)
E O Field, F Mauro, K Hellmann
Cancer Chemotherapy and Pharmacology
|
January 1, 1987
Reduction of vincristine toxicity by Cronassial
K Hellmann, G E Hutchinson, K Henry
Nature
|
May 9, 1970
Mode of action of the cytostatic agent "ICRF 159"
H B Sharpe, E O Field, K Hellmann
Parasitology Research
|
August 21, 2003
The anthelmintic efficacy and the safety of a combination of imidacloprid and moxidectin spot-on in cats and dogs under field conditions in Europe
K Hellmann, T Knoppe, I Radeloff, et al.
Parasitology Research
|
October 18, 2005
Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study
K Krieger, J Heine, P Dumont, et al.
British Journal of Cancer
|
August 1, 1974
Proceedings: Analysis of the antimetastatic action of the antimitotic agent ICRF 159
K Hellmann, S E James, A J Salsbury
Page
of 12
Search research articles
Search
Showing results (51-60 of 116) with videos related to
Sort By:
Page
of 12
Cancer Research
|
April 1, 1974
Histological analysis of the antimetastatic effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane
A J Salsbury, K Burrage, K Hellmann
British Medical Journal
|
November 7, 1970
Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic
A J Salsbury, K Burrage, K Hellmann
European Journal of Cancer & Clinical Oncology
|
June 1, 1989
The pyrimido-pyrimidine derivatives RA233 and RX-RA85 affect cell cycle distribution of two murine tumour cell lines
R B Lichtner, G Hutchinson, K Hellmann
Cancer Chemotherapy and Pharmacology
|
January 1, 1982
Razoxane penetration into the cerebrospinal fluid of rats
N Greig, F Xiao-Chang, K Hellmann
Cancer Chemotherapy Reports
|
December 1, 1971
Blood clearance of ICRF 159 (NSC-129943)
E O Field, F Mauro, K Hellmann
Cancer Chemotherapy and Pharmacology
|
January 1, 1987
Reduction of vincristine toxicity by Cronassial
K Hellmann, G E Hutchinson, K Henry
Nature
|
May 9, 1970
Mode of action of the cytostatic agent "ICRF 159"
H B Sharpe, E O Field, K Hellmann
Parasitology Research
|
August 21, 2003
The anthelmintic efficacy and the safety of a combination of imidacloprid and moxidectin spot-on in cats and dogs under field conditions in Europe
K Hellmann, T Knoppe, I Radeloff, et al.
Parasitology Research
|
October 18, 2005
Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study
K Krieger, J Heine, P Dumont, et al.
British Journal of Cancer
|
August 1, 1974
Proceedings: Analysis of the antimetastatic action of the antimitotic agent ICRF 159
K Hellmann, S E James, A J Salsbury
Page
of 12